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Abstract
Background: Hepatitis E virus (HEV) is one major cause of acute clinical hepatitis among humans throughout the
world. In industrialized countries an increasing number of autochthonous HEV infections have been identified over
the last years triggered by food borne as well as – to a much lower degree – by human to human transmission via
blood transfusion. Pigs have been recognised as main reservoir for HEV genotype 3 (HEV-3), and zoonotic
transmission to humans through undercooked/raw meat is reported repeatedly. The minimal infectious dose
of HEV-3 for pigs is so far unknown.
Results: The minimum infectious dose of HEV-3 in a pig infection model was determined by intravenous inoculation
of pigs with a dilution series of a liver homogenate of a HEV infected wild boar. Seroconversion, virus replication and
shedding were determined by analysis of blood and faeces samples, collected over a maximum period of 91 days. A
dose dependent incubation period was observed in faecal shedding of viruses employing a specific and sensitive PCR
method. Faecal viral shedding and seroconversion was detected in animals inoculated with dilutions of up to 10− 7.
This correlates with an intravenously (i.v.) administered infectious dose of only 6.5 copies in 2 ml (corresponding to 24
IU HEV RNA/ml). Furthermore the first detectable shedding of HEV RNA in faeces is clearly dose dependent.
Unexpectedly one group infected with a 10− 4 dilution exhibited prolonged virus shedding for more than 60
days suggesting a persistent infection.
Conclusion: The results indicate that pigs are highly susceptible to i.v. infection with HEV and that the swine
model represents the most sensitive infectivity assay for HEV so far. Considering a minimum infectious dose
of 24 IU RNA/ml our findings highlights the potential risk of HEV transmission via blood and blood products.
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Background
Hepatitis E is caused by Hepatitis E virus (HEV) which
is a major cause of acute hepatitis throughout the world
with a total number of 44,000 HEV-related deaths in
2015 [1]. Hepatitis E virus is a small, quasi-enveloped,
single-stranded RNA virus and a member of the Hepe-
viridae family. Novel taxonomic classification consists of
the two genera Piscihepevirus and Orthohepevirus
encompassing species A-D. All mammalian HEV isolates
have been attributed to species Orthohepevirus A [2] and
are further grouped into genotypes 1–8. Although
displaying a highly diverse group on molecular level, all
genotypes evidently belong to one serotype [3, 4].
Genotype 1 (HEV-1) and 2 (HEV-2) are restricted to
humans and are the main cause of endemic outbreaks in
developing countries in Asia, Africa and Central Amer-
ica [5, 6]. The transmission of these isolates mainly
occurs by the faecal-oral route due to poor sanitation
and contaminated water [3].
HEV genotypes 3 (HEV-3) and 4 (HEV-4) dominate in
developed countries and are the main source for autoch-
thonous human cases [7]. In Europe, North America,
Australia and New Zealand HEV-3 is reported as causa-
tive agent for these autochthone HEV infections [8, 9].
In addition, infections with gt4 have been observed in
China and Japan [10–12]. Besides humans various wild
and domesticated animal species such as wild boar and
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pigs [13] have been found to carry HEV-3 and HEV-4;
HEV-3 has also been detected in deer [14, 15] and rab-
bits [16, 17]. HEV-3/4 therefore is a zoonosis and pigs as
well as wild boar represent the main reservoirs [7, 18].
Domestic pig populations worldwide frequently include
viraemic animals and high HEV seroprevalences on herd
level [5, 19, 20]. The exact pathogenesis of the HEV in-
fection in pigs has still to be clarified. Naturally the
infection occurs by faecal-oral transmission route which
has been experimentally shown by a number of studies
[21–24], albeit the intravenous infection is used most
frequently in experimental challenge studies [22, 24–29].
Infected animals have high viral loads of HEV RNA
mainly in the liver accompanied by faecal virus shedding
in high concentrations [22, 23, 25, 26, 28]. Remarkably,
no clinical symptoms were observed in general [5, 22,
25, 26]. Domestic pigs are a suitable and sensitive model
for HEV-3 infection studies since they are also suscep-
tible to human HEV-3 isolates [27].
The HEV-3 transmission from animals to humans via
the consumption of infected undercooked/raw meat has
been documented in numerous cases [7, 9]. Further-
more, HEV has been detected in processed food prod-
ucts like sausages in Germany [30], Italy [31] and France
[9]. Regional distinctions such as raw meat consumption,
liver delicacies and close proximity to livestock can have
an influence on the exposure towards HEV [8, 32]. Add-
itionally, people with work-related exposure to reservoir
animals such as veterinarians, slaughterhouse personal,
hunters or stable hands show significantly higher sero-
prevalences compared to the general population [33, 34].
In general HEV causes a wide range of symptoms,
from subclinical to acute hepatitis with icterus up to ful-
minant hepatic failure [13]: The strictly human patho-
genic genotypes HEV-1/2 the main source of endemic
outbreaks – cause frequently an acute self-limited hepa-
titis with icterus and affect in general younger patients
[35]. HEV-1 infections in pregnant women are often
associated with severe courses, especially in the third tri-
mester [3, 13]. HEV-3 and HEV-4 strains can addition-
ally trigger extrahepatic manifestations but exhibit
significantly lower mortality [36]. In contrast to HEV-1,
HEV-3 infections can cause chronic and persistent infec-
tions mainly in immunocompromised patients [37, 38].
So far the infectivity of HEV is not clearly understood
and difficult to determine and due to the lack of a sensi-
tive cell culture system. Since domestic pig are highly
susceptible to HEV the porcine model was selected to
perform an endpoint titration study based on the appli-
cation of serial dilutions of a HEV-3 positive liver hom-
ogenate. Since swine share many similarities with
humans in physiology and immunology the determin-
ation of the minimal infectious dose provides important
indications also for HEV infectivity in humans.
Results
Inoculum
The infection studies were carried out using tenfold
dilutions of the inoculum from 10− 2 up to 10− 9. Corre-
sponding ct-values, copy numbers and IU are summa-
rized in Table 1. 3.7 IU correspond to 1 copy/μl RNA
which was calculated from standard curves of both PCR
assays used in this study [39] (Additional files 1 and 2).
According to this calculation, a 10− 2 dilution of the
experimentally infected liver contained 9.4 × 105 copies
(3.4 × 106 IU) in 2ml respectively.
Clinical parameters and pathology
Through-out the whole observation period none of
the animals showed a febrile response or any clinical
signs consistent with hepatitis. Additionally, no signs
typical for viral hepatitis were seen at gross examin-
ation after necropsy.
Virus detection in faeces and serum intra-vitam
Viral RNA was detected in the faeces of all groups up to
a dilution of 10− 7. In the first experimental set up cover-
ing homogenate dilutions from 10− 2 to 10− 4 over an
observation period of 27 days (Fig. 1) viral shedding was
observed in all three groups. First detection of viral
RNA was in the group 10− 2 at 9 dpi (pig T1–14)
followed by groups 10− 3 at 15 dpi and 10− 4 at 17 dpi.
Due to this delayed onset it was decided to extend the
observation period for the second experimental set up
for up to 91 days. The second 10− 4 group started with
viral shedding also at 17dpi, followed by the group 10− 5
at 27 dpi. Viruses started to be shed within a time frame
of six days for all animals within all groups of the first
experiment and these two groups in the second experi-
ment. In the remaining groups inoculated with higher
HEV dilutions, a more variable time frame of viral









1 10–2 25,6 13,010 467.853,40 935.706,80 3.443.401,02
10–3 28,7 139 49.642,46 99.284,92 365.368,51
10–4 33,0 5,61 2.003,56 4.007,11 14.746,17
2 10–4 32,2 10 3.607,11 7.214,22 26.548,33
10–5 35,5 0,91 325,71 651,42 2.397,23
10–6 no ct – – 65,1a 239,70*
10–7 no ct – – 6,5a 24,00*
10–8 no ct – – 0,65a 2,40*
10–9 no ct – – 0,065a 0,24*
Viral copy numbers were calculated from CT values determined by RT-qPCR
(HEV copies/μl RNA), volume of dose applied was 2ml, tcalculated based on
HEV copies/μl RNA (see Additional files 1 and 2)aextrapolated values
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Fig. 1 Results of the RT-qPCR from faeces and the species independent HEV-Ab ELISA; the figures display the individual curves of viral RNA in
faeces and the detection of total serum antibodies in correlation to days after infection
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shedding was obvious. In group 10− 6, pig T2–24 shed
from 21 dpi - 30 dpi. The remaining animals of this
group started one by one after 27 dpi, 34 dpi, and 37
dpi. In group 10− 7 pigs shed the virus until end of ex-
periment; pig T2–17 started shedding virus at 37 dpi,
while the other animals in this group started shedding at
55 dpi, 58 dpi and 62 dpi.
The majority of animals had between 1.3 and 51.7
HEV copies/μl RNA in the10% faecal suspension initially
and reached a plateau of about 103 HEV copies/μl RNA
eventually. Only individual animals of the 10− 4 and the
10− 5 group of the second experiment (Fig. 1) occasion-
ally excreted six fold higher viral loads (up to 6.6 × 103
HEV copies/μl RNA) in their faeces.
Viral clearance was detected in group 10− 2 in which
shedding of HEV RNA in faeces ceased in three out of
four pigs (pig T1–12, pig T1–13, T1–14) after a mean of
7 d (±2.7). One individual (pig T1–11) remained positive
till the end of the observation period on day 23. Unfor-
tunately on day 27 (necropsy) no faeces was available
from this animal for testing. In the 10− 3 group only one
animal (pig T1–08) cleared the virus before necropsy
(27 dpi) 23 days dpi. No viral clearance was observed in
the 10− 4 group in both experiments even after 91 dpi.
For group 10− 5 an at least 18d period of faecal shedding
was seen with no clearance till the end of the observa-
tion period of 49dpi. In group 10− 6 virus clearance oc-
curred at very diverse intervals including 11d (pig T2–
24), 21d (pig T2–23), 28d (pig T2–22) and more than
35d (pig T2–21), and in group 10− 7 the animals shed
virus for at least 36d (pig T2–17) or for 7, 4 or 1 days
before being euthanized. Neither in the dilution 10− 8
nor in the dilution 10− 9 signs of virus replication or
shedding were observed at all over a period of 76dpi.
The detection of HEV RNA in serum was only spor-
adic and with low viral amounts (Additional files 2).
Detection of viral RNA in serum samples at more than
two consecutive sampling time points was only ob-
served for groups 10− 4/2 (pig T2–29, pig T2–30, pig
T2–31, pig T2–32), 10− 5 (pig T2–25, pig T2–27, pig
T2–28) and 10− 7 (pig T2–17) after 24 dpi, 34 dpi and
58 dpi respectively.
Infectivity titre of liver
The infectivity in the liver tissue used for the inoculation
can be quantified by the calculation of an ID50 according
to Spearman and Kärber [40, 41] under particular
assumptions: Restriction to an observation period of 27
days and in the case of longer incubation times the first
positive animal within the group. The calculated titre
was 6.3 × 105 ID50 per 1 ml liver tissue which represents
4.4 × 105 infectious units/ml. Setting this result in rela-
tion to the quantitation of HEV RNA in the liver
inoculum 773 IU HEV RNA correspond to one infec-
tious unit (for calculations see Additional file 3).
Antibody detection
Seroconversion started in all animals after the excretion
of viral RNA in faeces. Pigs seroconverted in group 10− 2
at 17 dpi, group 10− 3 at 23 dpi, group 10− 4 at 27 dpi,
10− 5 at 37 dpi, 10− 6 at 27 dpi and 10− 7 at 58 dpi. The
interval between detection of HEV in faeces and sero-
conversion was 7.0 ± 1.0 days for group 10− 2, 11 ± 1.7
days for group 10− 3, 12.8 ± 12.8 days for group 10− 4,
16.0 ± 3.5 days for group 10− 5, 13.3 ± 7.2 days for group
10− 6, 31.0 ± 0.0 days for group 10− 7. In one case (pig
T2–32) seroconversion was determined prior to virus
detection which can be explained by the oscillation of
corresponding OD values around the cut-off at sampling
days 27 and 30 followed by a strong increase from day
34 on. HEV antibodies were assessed by the species in-
dependent HEV-Ab ELISA detecting total serum anti-
bodies (e.g. IgG, IgM, IgA) in blood (Fig. 1). In the
Priocheck HEV Ab porcine ELISA which only detects
IgG, seroconversion was generally observed three to ten
days later (Additional file 4). An exception was found for
animals in the 10− 7 group, where seroconversion was
detected by both ELISA’s at the same day. No serocon-
version was observed in the 10− 8 and 10− 9 groups.
Virus detection in organs
All animals of the study were subjected to necropsy and
blood, faeces, bile and tissue samples were taken and
analysed by RT-qPCR for viral RNA (Tables 2 and 3).
This included four different liver loci, the gallbladder,
the hepatic lymph nodes, the spleen, the mesenteric
lymph nodes and the mandibular lymph nodes. All ani-
mals which showed faecal shedding at necropsy were
found HEV RNA positive in the bile and at least in two
loci of the liver. The viral load of the gallbladder was
considerably lower compared to bile itself. In pancreas
no viral RNA was detected. In all other organs tested,
individuals sporadically showed positive results. Corre-
sponding data are shown in Tables 2 and 3.
Sequencing
The sequence of the hypervariable region of the inocu-
lum (sequence and reference sequence KP294371 are
shown in Additional file 5) was analysed by nested
RT-PCR to monitor possible nucleotide exchanges after
replication and passage through infected pigs. The ori-
ginal sequence displays a characteristic C/T wobble
sequence at position 2200. Likewise virus sequences
from isolates from pigs of dilution groups 10− 2, 10− 3,
10− 4, 10− 5, 10− 6 and 10− 7 displayed C/T polymorphisms
at this site. In addition to the nucleotide 2200 poly-
morphism one isolate (derived from animal (T2–28))
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had a C to T exchange at position 2322. The alignment
was done with a previously published full genome
(KP294371). The wobble sequence translates into a
proline/serine exchange. The point mutation in animal
T2–28 was silent.
Horizontal controls
The two horizontal controls (T1-01c, T1-02c) showed no
clinical or molecular evidence for a HEV infection and
faecal samples were always negative for HEV RNA. How-
ever, one liver lobe of pig T1-01c gave a positive
RT-qPCR result (shown in Table 2).
Discussion
An increasing number of human hepatitis E genotype 3
(HEV-3) infections has been observed in developed
countries in the last decade. This is accompanied by a
substantial proportion of HEV RNA positive blood prod-
ucts and a growing number of transfusion transmitted
HEV infections [8]. The high incidence represents a
major health concern especially for immunosuppressed
patients or people with pre-existing liver diseases. This
raises the question of the minimal infectious dose for
intravenously applied HEV-3. For this purpose - based
on the similarities of pig and human physiology and the
assumption of pigs as reliable animal models for human
HEV infection, a comprehensive dose-titration study was
carried out in domestic pigs to determine the minimum
infectious dose. The titration was based on serial dilu-
tions of a HEV RNA positive liver homogenate of an
experimentally infected wild boar [23]. It ranged from a
10− 2 dilution up to a 10− 9 dilution and was applied into
groups of 4 pigs each. Seroconversion and viral shedding
was observed up to a 10− 7 dilution which corresponds
to a minimal infection dose of 6.5 copies in 2 ml total
volume (according to 24 IU HEV RNA) for swine. In
contrast to pigs, the infectious dose for humans is
reportedly significantly higher: the transfusion of a plate-
let concentrate with residual plasma containing 7056–
8892 IU HEV RNA was infectious [59]. In another study,
the minimal infectious dose of HEV through transfusion
was 3.6 × 104 IU [42]. A minimal infectious dose for
humans in the order of 10,000 IU HEV RNA was also
reported by F. Rossi, IPFA [43]. However, a direct correl-
ation is not possible, since our pig study evaluated liver
derived HEV in contrast to human blood (plasma) prod-
ucts. The reduced infectivity of HEV positive plasma
samples has been recently demonstrated in human liver
chimeric mice [44]. In monkeys, intravenous HEV infec-
tion studies were performed as well, however generally
using inocula from faecal samples. The used dosages
encompassed titers of 6.4 log10 copies/ml of a HEV-3
isolate [45] as well as 2.45 × 105 IU/ml for a HEV-4 and
7.51 × 105 IU/ml for a HEV-1 isolate [46]. Similar
dosages were used in a recent study [47] using different
HEV-1 isolates (3.5–6.4 log10 IU/ml) and HEV-3 isolates
(2.5–9.5 log 10 IU/ml). In each case cynomolgus mon-
keys could be productively infected.
All infected animals remained asymptomatic and
showed no signs of illness such as fever, reduced alert-
ness nor weight loss throughout the experiment which is
in line with previous studies in domestic pigs [24, 25,
28]. So far, only singular cases of icterus in HEV infected
pigs [27] as well as the elevation of liver specific en-
zymes in infected wild boar [23] have been reported.
This study established faeces as appropriate source to
determine the course of virus replication in pigs via
RT-qPCR due to weak and sporadic detection of viral
RNA in serum with a general lower viral load. This is in
accordance with previous reports [22, 48]. It is of special
significance that the calculated copy number of 5 copies
/ml in the 10− 7 dilution lies below the limit of detection
of both PCR assays but is sufficient to infect pigs by the
intravenous route. This is in accordance with a previous
pig titration study where infectivity was observed below
the RT-PCR detection limit [28]. In addition a clear cor-
relation between applied dosage and incubation period
was determined: A 10− 2 dilution of the inoculum in-
duced viral shedding at 9 dpi, followed by virus shedding
at 15 dpi (10− 3 dilution), 17 dpi (10− 4 dilution) and 27
dpi (the 10− 5 dilution) in at least one pig per group, on
average 30 dpi (10− 6 dilution) and on average 51 days
(10− 7 dilution). The subsequent dilutions also induce
growing individual differences in onset of virus shedding
varying from 6 to 9 days (10− 4 group), 10–18 days (10− 6
group) up to 16 days (10− 7 group). The increasing exten-
sion of incubation period raises the question regarding
replication site and persistence of the virus. Further dilu-
tions (10− 8, 10− 9) of the inoculum induced no HEV in-
fection. In contrast, in the aforementioned study none of
the animals inoculated with dilutions below 10− 4 were
infected [28]. However a direct comparison of both
studies was not possible, since the viral load was deter-
mined by Genomic Equivalents (GE/ml) and due to the
use of faecal material for intravenous inoculation. Both
sources are able to induce virus replication as reported
in multiple studies. A comparison of these studies
regarding onset and duration of virus shedding and sero-
conversion is difficult because applied doses are incom-
parable and inoculum sources were different: After i.v.
application of HEV positive faeces (10% suspension)
virus detection in faeces started 3 dpi [25, 26] or 7–14
dpi [28] and took 1–3 weeks. Using inoculum from a
HEV positive pig derived bile led to virus shedding from
3 dpi on [22]. Using high titre liver homogenates i.v.
infected pigs started to excrete virus between 2 and 7
days and continued 12–52 days [24, 29]. In another
study faecal RNA samples of infected pigs were detected
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at day 9 to 19 and faecal HEV excretion lasted 21–30
days [21]. Interestingly both sources harbour significant
differences because blood as well as hepatocyte/liver
derived HEV particles are enveloped and covered with
cellular membranes in contrast to non-enveloped HEV
from bile or faeces [49–51]. This envelope has been also
detected in cell-culture produced HEV particles [50, 52]
and appears to modulate infectivity in vitro as well as in
vivo. The generation of quasi-enveloped HEV particles
by hepatocytes and hepatoma cell lines [51] strongly in-
dicates that HEV from liver homogenate harbors an en-
velope as well, but experimental data are still lacking.
Cell culture derived enveloped HEV revealed an almost
tenfold lower infectivity compared to non-enveloped fae-
ces derived HEV in cell culture [53], which may be a
consequence of inefficient cell attachment [54]. How-
ever, the findings are complicated by the fact, that
human liver homogenate as well as faeces from HEV
positive patients is capable to infect humanized chimeric
mice in contrast to human plasma or cell-culture de-
rived HEV [55]. Therefore the question how biochemical
properties of HEV particles modulate infectivity needs
further investigation.
A presumably faecal-oral transmission of HEV was ob-
served by one of the horizontal controls (pig T1-01c)
within the 10− 4 group. The animal exhibited a HEV
positive liver as determined by necropsy at 27dpi. The
first onset of viral shedding in this group was on 17dpi
from pig T1–06 which leads to a maximum incubation
period of 10 days. The reported periods between oral in-
take and HEV particles shed in faeces can range from
7.2d [24] up to 22d [22] and possibly even longer.
Antibody response and seroconversion were assessed
by two ELISAs with different specifications: The
AXIOM ELISA was a multispecies test for detecting
total serum antibodies against HEV (including IgM, IgA
and IgG) whereas the PrioCheck ELISA only detected
porcine HEV specific IgG antibodies. Specific porcine
IgM ELISAs were not available. In general the serum
samples were confirmed positive in the AXIOM ELISA
three to ten days before the porcine specific IgG ELISA
which is consistent with a primary IgM related immune
response followed by IgG response. However, no reliable
conclusions can be drawn about the specific occurrence
of IgM or IgA or of a mixture of both during the pri-
mary immune response. In any case IgA antibodies play
an important role in the human immune response
against HEV [55, 56].
Virus clearance could be observed in different
groups examined: Three animals in group 10− 2, one
individual from 10− 3 and three from the 10− 6 dilu-
tion group cleared the infection within 7d (±2,7d), 8d
and 9d up to 27d respectively. All remaining animals
were subjected to necropsy prior to a possible virus
clearance. All animals of the second 10− 4group dis-
played a prolonged infection where HEV RNA was
detectable in faeces for more than 62 days. Necropsy
samples of this group harboured high viral load in
bile and liver samples. The 10− 5 group exhibited fae-
cal viral shedding for 22d and individual animals from
group 10− 6 and 10− 7 group for 35d and 36d, respect-
ively. Again, all animals showed high viral loads in
bile and liver at necropsy. In general, HEV is consid-
ered to be a transient infection and viral clearance
usually occurs within three weeks after first occur-
rence in faeces [22, 24]. The long-term viral shedding
for more than 32 up to 62 days is therefore uncom-
mon and possibly indicates a chronic or persistent
infection. Only rare data from similar studies are
available: HEV shedding was significantly increased by
co-infection with Porcine Reproductive and Respira-
tory Syndrome Virus (PRRSV) and extended from 9.7
to 48.6 days [57]. However, all animals in this study
had been pre-tested to be negative for PRRSV as well
as Porcine circovirus 2 (PCV2). This analysis was
continued with faeces samples from the second 10− 4
group encompassing the whole observation period, to
exclude a newly or internal acquired PRRSV and
PCV2 infection. Again all samples were negative for
both viruses. All animals showing prolonged viral
shedding belonged to the dilutions 10− 4 or higher, in-
dicating a correlation between inoculated virus load
and prolonged viral shedding. The 10–4 g.
Another research study showed extended virus shed-
ding in wild boars for more than 16 weeks [48]. Interest-
ingly the animals showed high antibody titers as well,
with apparently no influence on virus shedding and rep-
lication. The presence of neutralising antibodies within
the context of a HEV infection has been shown in vivo
[58, 59] and in vitro [58–60]. Other factors such as age
and individual immune status should be taken into
account as well.
It may be of interest that in humans various cases of
chronic HEV-3 infections were reported in immunosup-
pressed patients [61]. For all other genotypes such a
correlation has not been made so far.
Conclusion
In conclusion, this study determined an extremely low
minimum infectious dose of HEV to elicit a productive
infection in pigs. Additionally our work demonstrated a
dose dependent incubation time in pig resulting in a de-
layed onset of virus replication and shedding. Moreover
the study emphasises the potential risk of HEV transmis-
sion in humans via blood and blood products. Finally
further investigations should be undertaken to determine
and compare the infectivity through oral transmission.
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Methods
Inoculum
The inoculum used in this study was prepared from a
highly HEV RNA positive liver of an experimentally
infected wild boar from a previous HEV-3 infection
study [23].
20 g of liver tissue was grounded with mortar, pestle
and sterile sea sand. The homogenate was then diluted
1:5 with sterile 1x phosphate buffered saline (1xPBS) to
obtain a 20% dilution and centrifuged at 4400 g for 15
min at 4 °C. The supernatant was eventually sterile-fil-
tered through 0.22 μm MILLEX-GP Syringe Filter Unit
(Millipore, Ireland), aliquoted and stored at − 80 °C. The
inoculum was titrated with the Logarithmic dilutions in
sterile 1xPBS starting from a 10− 2 dilution (referring to
the original liver tissue) to 10− 9. The 10− 2 dilution was
sterile filtered prior to inoculation and further dilutions.
The corresponding inocula were prepared shortly before
inoculation and kept on ice until use and administered
intravenously (i.v.) to 4 animals/group.
Experimental design
The competent authority of the Federal State of
Mecklenburg Western-Pomerania approved all described
animal experiments based on European Directive 2010/
63/EU and associated national regulation (reference
number in Germany LALLF M-V/TSD/7221.3–2.1.014/
10, LALLF M-V/TSD/7221.3–2.1-017/13).
For this study 38 domestic pigs (Large White breed)
from a commercial breeder (animal husbandry, 18,196
Dummerstorf, Germany) were acquired and housed
under containment level 3** conditions. Healthy animals
of compatible sizes and ages were allocated randomly to
groups by animal technicians. Social incompatibilities
were taken into account in few instances for animal
welfare reasons. As the study was a titration experiment
with a clear cut yes/no readout, the number of animals
per group was set as described together with a
biostatistician. The experimental design was part of the
individualized animal experimental license (reference
number in Germany LALLF M-V/TSD/7221.3–2.1.014/
10, LALLF M-V/TSD/7221.3–2.1-017/13 according to
the Germany animal welfare law (§7 paragraph 1 phrase
2 TierSchG) which was applied for and given after scien-
tific and ethical assessment by an independent advisory
board. After entry, the animals were divided into the
experimental groups and held in quarantine for 2 weeks.
Individuals of each group were housed together whereas
each group was held in a separate stable unit. Complete
change of clothes was mandatory before entry of each of
the rooms. All animals were pretested for HEV and
yielded negative PCR findings in faeces and serum as
well negative HEV ELISA results. Due to facility limita-
tions the study was divided in two experiments. The
groups were randomly formed consisting of 4 animals
each as described in Table 4. Two horizontal transmis-
sion control animals were included and kept with the
10− 4 group. A blinded experimental and analysis design
was not possible as researchers and animal technicians
were supposed to carry out husbandry and experimental
work in a defined way in order to mitigate (cross-) con-
tamination risks: every day animal manipulations started
in the low dose challenged animals, followed by
intermediate dose challenged pigs and in high-dose ani-
mals eventually. Moreover, as only standardized quanti-
tative data were obtained (e.g. body temperatures, qPCR
(Ct-values and copy numbers) and ELISA derived data),
blinding was not considered necessary.
After at least two weeks of acclimatisation negative
HEV RNA and Anti-HEV-antibody results were recon-
firmed by Rt-qPCR and ELISA. Additionally samples
were examined by a novel multiplex PCR [62] (Results
not shown) to exclude an influence of co-infection with
other viral diseases (PRRSV, PCV2). The inoculation was
done with 2.0 ml inoculum intravenously given into the
Vena cava cranialis.
Table 4 Experimental set up for the titration of highly HEV positive liver tissue in log steps in the porcine model
Exp. No. Dilution = Group Animal identity Animals Sex Age at inoculation Observation period
infected horizontal control in weeks
1 10−2 Pig T1–11, −12, −13, −14 4 – f/m 10 27dpi
10−3 Pig T1–07, −08, −09, −10, 4 – f/m 10 27dpi
10−4 Pig T1-01c -02c,-03, −04, −05, −06 4 2 f/m 10 27dpi
2 10−4 Pig T2–29, −30, −31, −32 4 – m 11 91dpi
10−5 Pig T2–25, −26, −27, −28 4 – f/m 11 49dpi
10−6 Pig T2–21, −22, −23, −24 4 – f 11 63dpi
10−7 Pig T2–17, −18, −19, −20 4 – f/m 11 63dpi
10−8 Pig T2–13, −14, −15, −16 4 – m 11 77dpi
10−9 Pig T2–09, −10, −11, −12 4 – f 11 77dpi
The dilution step of the homogenate as assigned the group designation, f-female, m-male, dpi-days post infection, −- none
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Animal behaviour and rectal body temperatures were
checked daily. As described in previous studies body
temperatures over 40 °C for at least two consecutive days
were considered a febrile response [23, 48]. Depression,
diarrhoea, vomitus, icterus, ascites and neurological
symptoms were considered signs of acute hepatitis and
would have led to an immediate removal and euthanasia
of the animal.
During the experiments blood and faecal samples were
taken regularly every two to three days. Blood was
allowed to clot for 30 min at room temperature and then
centrifuged at 2300 g for 12 min. Serum was then col-
lected, aliquoted and stored at − 20 °C. From the faecal
samples a 10% faecal suspension was made using 0.89%
NaCl-solution. After vortexing and centrifugation (4400
g, 4 °C, 20 min) the supernatant was sterile filtrated
using a sterile 0.22 μm MILLEX-GP Syringe Filter Unit
(Millipore, Ireland) and stored at − 20 °C. This solution
was the starting point for RNA extraction.
At the end of the observation period all animals were
slaughtered (electro stunning followed by exsanguin-
ation). Animals were euthanized by a veterinarian fol-
lowing EU and German animal welfare regulations and
carcasses necropsied by a trained veterinary pathologist
assisted by a necropsy technician. Necropsies were per-
formed and samples from blood, faeces and bile as well
as different tissue samples were taken for RNA extrac-
tion and stored at − 20 °C. Retrieved tissue samples were
immediately immersed in 4% neutral buffered formalin.
RNA and antibody detection
A sample volume of 140 μl of serum, bile and faecal fil-
trates were extracted manually with the QIAmp® Viral
RNA Mini Kit (QIAGEN GmbH, Hilden Germany) fol-
lowing the manufactures instructions and eluated in
50 μl buffer. Manual RNA extraction from tissue samples
was performed with the RNEasy® Mini Kits (QIAGEN
GmbH, Hilden Germany). For this purpose 10 mg of a
tissue sample was homogenized in 600 μl RLT buffer
using TissueLyser II ® (Qiagen). After centrifugation the
supernatant was used for RNA extraction according to
manufacturer’s instructions. A heterologous internal
control [63] was added to each extraction sample.
Obtained RNA was stored at − 80 °C until further use.
To monitor the course of the infection a diagnostic
quantitative real-time RT-PCR (RT-qPCR) targeting a
fragment of ORF3 was performed. Primer, probes and
protocol were used as previously reported [23, 39]. Each
reaction containing 25 μL had a final primer concentration
of 0.8 μM and of 0.1 μM probe and 5 μl RNA. RT-qPCR
was carried out using the Quanti Tect Probe RT-PCR Kit
(QIAGEN GmbH). The CFX96™Real-Time System (Bio-
Rad Laboratories GmbH, Munich, Germany) was set to
50 °C for 30min for reverse transcription followed by
denaturation/activation 95 °C for 15min. DNA amplifica-
tion was performed in 45 cycles consisting each of 95 °C
for 10 s, 55 °C for 25 s and 72 °C for 25 s in immediate suc-
cession. The quantification of RNA (HEV copies/μl RNA)
was performed by a standard curve based on serial dilu-
tions of a HEV standard, which was included in each
qRT-PCR run (Additional file 1). The copy number of
HEV standards was calculated by a synthetic calibrator
which consists of the qRT-PCR amplicon (81 nucleotides)
and a T7-Promotor sequence at the 5′-end to allow in
vitro transcription [39]. International Units/ml (IU) were
calculated from the WHO International standard for
HEV. This standard was provided by the Paul-Ehrlich-
Institut (PEI), Langen, Germany (PEI code 6329/10). All
RT-qPCR results are given in HEV copies/μl RNA (origin-
ating from 50 μl elution volume). The corresponding cop/
ml (originating from 140 μl fluid sample) were calculated
by conversion factor of 357, 14 (elution volume divided by
fluid sample volume) and is depicted in Additional file 2.
The limit of detection of about 1 cop/μl is reached at
ct-values of ~ 35. The limit of quantification corresponds
to the 10− 4 HEV standard at 7 copies/μl. Viral loads below
the lowest HEV standard were retested by an alternative
HEV specific qRT-PCR [64].
To monitor the immunological responses, the serum
samples were tested with two commercially available
HEV ELISA kits. One was the species independent
HEV-Ab ELISA (AXIOM, Bürstadt, Germany) [23] de-
tecting total serum anti-HEV-antibodies. The other was
the porcine specific Priocheck HEV Ab porcine ELISA
(Mikrogen GmbH, Neuried, Germany), which is specific
for serum Anti-HEV-IgG. Both were carried out and
interpreted as described by the manufacturer.
Sequencing
To monitor and verify the identity of the inoculated
compared to the replicated/excreted virus genome a 348
nucleotide long partial sequence of the hypervariable
region (HVR) was recovered from corresponding faecal
samples. SYBR Green-RT-qPCR followed by a SYBR
Green nested PCR both with melting curve analysis was
performed as described [39]. The resulting cDNA was
sequenced by a commercial provider (Eurofins Genom-
ics GmbH, Ebersberg, Germany).
Additional files
Additional file 1: Amplification curve of HEV specific qRT-PCR. A)
Amplification curve of HEV specific qRT-PCR targeting the HEV standard (red
line) and the RNA extracts from the inocula (blue line). B) Standard curves
were obtained by Ct values plotted against the log of starting quantity. C)
Obtained Ct values and determined copy numbers (DOCX 219 kb)
Additional file 2: Determination of the conversion factor from copies
per μl RNA to IU of the WHO standard (DOCX 16 kb)
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Additional file 3: Calculation of the Infectivity titer of the Liver Used for
Inoculation (DOCX 16 kb)
Additional file 4: Results of the RT-qPCR from serum and the porcine
IgG HEV-Ab ELISA; The graphs display the individual curves of viral RNA
in serum and the detection of Anti-HEV-IgG antibodies in correlation to
days after infection (DOCX 462 kb)
Additional file 5: Alignment of the hypervariable region. Alignment
done with Geneious version 10.2 created by Biomatters. Available from
https://www.geneious.com (DOCX 244 kb)
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Ab: Antibody; dpi: Days post inoculation; ELISA: Enzyme-linked
immunosorbent assay; f: Female; gt: Genotype; HEV: Hepatitis E Virus;
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